STADA Arzneimittel (SAZ) PT Set at €74.40 by Nord/LB

Nord/LB set a €74.40 ($88.57) price target on STADA Arzneimittel (ETR:SAZ) in a report issued on Wednesday, December 20th. The brokerage currently has a sell rating on the stock.

A number of other analysts also recently weighed in on the stock. Commerzbank set a €66.25 ($78.87) price target on shares of STADA Arzneimittel and gave the stock a sell rating in a report on Wednesday, December 20th. Independent Research set a €89.00 ($105.95) price objective on shares of STADA Arzneimittel and gave the company a neutral rating in a research note on Wednesday, December 20th. Warburg Research set a €74.40 ($88.57) price objective on shares of STADA Arzneimittel and gave the company a sell rating in a research note on Wednesday, December 20th. Finally, S&P Global set a €74.40 ($88.57) price objective on shares of STADA Arzneimittel and gave the company a sell rating in a research note on Friday, November 10th. Four analysts have rated the stock with a sell rating and two have assigned a hold rating to the company’s stock. The stock currently has an average rating of Sell and a consensus target price of €74.08 ($88.18).

Shares of STADA Arzneimittel (SAZ) remained flat at $€88.66 ($105.55) during trading on Wednesday. The company had a trading volume of 29,454 shares, compared to its average volume of 56,226. STADA Arzneimittel has a 1 year low of €46.31 ($55.13) and a 1 year high of €89.76 ($106.86). The company has a market cap of $5,530.00 and a P/E ratio of 58.33.

TRADEMARK VIOLATION NOTICE: “STADA Arzneimittel (SAZ) PT Set at €74.40 by Nord/LB” was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://stocknewstimes.com/2018/01/11/nordlb-reiterates-74-40-price-target-for-stada-arzneimittel-saz.html.

About STADA Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Analyst Recommendations for STADA Arzneimittel (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply